Irene Becklund Sells 472 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Irene Becklund sold 472 shares of the business’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $29.58, for a total value of $13,961.76. Following the completion of the transaction, the insider now owns 17,331 shares in the company, valued at approximately $512,650.98. This trade represents a 2.65 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Irene Becklund also recently made the following trade(s):

• On Monday, November 18th, Irene Becklund sold 472 shares of Hims & Hers Health stock. The stock was sold at an average price of $19.42, for a total value of $9,166.24.

Hims & Hers Health Price Performance

Shares of HIMS opened at $28.55 on Thursday. Hims & Hers Health, Inc. has a 12 month low of $8.09 and a 12 month high of $35.02. The stock has a fifty day moving average price of $25.46 and a 200 day moving average price of $21.19. The company has a market cap of $6.24 billion, a P/E ratio of 64.89 and a beta of 1.25.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. During the same quarter in the previous year, the company posted ($0.04) earnings per share. The company’s revenue for the quarter was up 77.1% compared to the same quarter last year. As a group, research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Institutional Investors Weigh In On Hims & Hers Health

Several large investors have recently made changes to their positions in the company. Renaissance Technologies LLC boosted its position in shares of Hims & Hers Health by 113.1% during the second quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock worth $121,936,000 after buying an additional 3,205,108 shares during the period. Wellington Management Group LLP raised its stake in Hims & Hers Health by 34.5% during the 3rd quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock valued at $63,446,000 after acquiring an additional 883,230 shares in the last quarter. Geode Capital Management LLC boosted its position in Hims & Hers Health by 12.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock worth $79,029,000 after acquiring an additional 482,177 shares during the period. Healthcare of Ontario Pension Plan Trust Fund grew its stake in shares of Hims & Hers Health by 164.1% in the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 528,142 shares of the company’s stock worth $10,663,000 after purchasing an additional 328,142 shares in the last quarter. Finally, State of Michigan Retirement System increased its holdings in shares of Hims & Hers Health by 177.8% during the second quarter. State of Michigan Retirement System now owns 500,000 shares of the company’s stock valued at $10,095,000 after purchasing an additional 320,000 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently commented on HIMS. Needham & Company LLC started coverage on shares of Hims & Hers Health in a research report on Thursday, August 22nd. They set a “buy” rating and a $24.00 price target for the company. Morgan Stanley began coverage on shares of Hims & Hers Health in a report on Tuesday. They set an “overweight” rating and a $42.00 price objective for the company. Bank of America lowered shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and cut their target price for the company from $32.00 to $18.00 in a research note on Thursday, November 14th. Deutsche Bank Aktiengesellschaft lifted their price target on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, November 6th. Finally, Piper Sandler restated a “neutral” rating and set a $21.00 price objective (up previously from $18.00) on shares of Hims & Hers Health in a research note on Tuesday, November 5th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $22.80.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.